The present disclosure relates to antibodies, for example monoclonal antibodies, and their use in clinical patient evaluation and therapy. The present disclosure further relates to a method for modulating the activity of human CXCL-1 protein (hereinafter, referred to as CXCL1). In an aspect, antibodies described herein are capable of being used as a medicament for the prevention and/or treatment of diseases involving CXCL1 function, for example, pathological angiogenesis and inflammatory diseases.

A peptide that binds specifically to neuropilin-1 (NRP1) without binding to neuropilin-2 (NRP2) is provided. A fusion protein, a fusion antibody, small-molecule drug, a nanoparticle, or a liposome, which comprises the peptide, and a pharmaceutical composition for treating or preventing cancer or angiogenesis-related diseases, and a composition for diagnosing cancer or angiogenesis-related diseases are provided. A polynucleotide encoding the peptide that binds specifically to NRP1 and a method for screening the peptide that binds specifically to NRP1 are provided. An antibody heavy-chain constant region Fc-fused peptide binding specifically to NRP1 has the property of binding specifically to NRP1, and thus when it is administered in vivo, it accumulates selectively in tumor tissue, and widens the intercellular space between tumor-associated endothelial cells to promote its extravasation and increases its tumor tissue penetration.

The present invention relates to a dual-targeting antibody targeting stem cell factor (SCF) and galectin-1 and a composition for preventing or treating angiogenesis-related diseases comprising the same. The present invention provides a dual-targeting antibody derived from a human monoclonal antibody which may effectively inhibit angiogenesis by simultaneously neutralizing SCF and galectin-1 involved in angiogenesis, and a pharmaceutical composition for preventing or treating angiogenesis-related diseases comprising the antibody. The dual-targeting antibody according to the present invention may effectively prevent or treat angiogenesis-related diseases by simultaneously neutralizing two targets involved in angiogenesis wherein the angiogenesis-related diseases cause hemorrhaging by blood vessels changing due to abnormal angiogenesis and thus increasing the permeability thereof.

The present invention relates to a composition for detecting hydrogen sulfide or measuring a concentration of hydrogen sulfide, and a composition comprising same as an effective ingredient for diagnosing or imaging in vivo inflammation, tissues having hypoxic damage, or cancer. The composition for detecting hydrogen sulfide or measuring a concentration of hydrogen sulfide according to the present invention, which comprises the compound represented by formula 1 (.sup.99mTc-alpha-hydroxy acid) having alpha-hydroxy acid labeled with .sup.99mTc, enables the detection or concentration measurement of hydrogen sulfide in in-vitro and in-vivo levels and, as such, can be advantageously used for detecting hydrogen sulfide and measuring a concentration of hydrogen sulfide and furthermore for discovering biological roles of hydrogen sulfide in vivo, especially, for detecting, imaging, and quantitatively measuring hydrogen sulfide in a disease selected from the group consisting of angiogenesis, inflammation, cancer, Alzheimer's disease, cardiovascular ischemia, and cerebrovascular ischemia, or in hypoxic tissues.

Pathogenic blood vessels are blood vessels that are not involved in the vascularization of normal organs but are in the pathogenic tissues such as the new blood vessels that drive vision diseases or the blood vessels in tumors that tumors depend on to survive. The current disclosure provides an advancement over typical anti-angiogenic strategies that target the generation of new blood vessels by providing compositions and methods that can selectively target and kill existing pathogenic blood vessels. The conventional antiangiogenic drugs or factors inhibit angiogenesis (the growth of new blood vessels), but cannot effectively kill existing pathogenic blood vessels. Agents, including small molecule compounds and antibodies, have been identified that bind to and activate PLXDC1 and PLXDC2 proteins, leading to effective killing of the endothelial cells in pathogenic blood vessels in vision diseases and in tumors that express these proteins. The disclosure thereby provides a novel modality for eliminating or reducing existing pathogenic blood vessels, thereby treating diseases such as diabetic retinopathy, age-related macular degeneration (AMD), retinopathy of prematurity, and cancer.

The present invention relates generally to the field of medical diagnostics, and more particularly to a method for determining a vascular endothelial growth factor-A (VEGF) isoform concentration pattern of a biological sample. A biological material is obtained from a premature infant. A VEGF isoform concentration pattern of the biological material is determined using at least a first cytokine and a second cytokine. The VEGF isoform pattern is compared to a reference VEGF isoform concentration pattern that conveys a baseline concentration of at least a first cytokine and a second cytokine. A normal VEGF isoform concentration pattern is determined when the VEGF isoform concentration pattern is within a threshold percentage of the reference VEGF isoform concentration pattern. The VEGF isoform concentration pattern conveys concentration levels of at least the first cytokine and the second cytokine. The biological material may be a blood or a fecal sample obtained from a premature infant.

The invention includes, in part, methods and compounds for diagnosing diseases and conditions characterized by altered threonyl-tRNA synthetase (TARS) activity, which include, but are not limited to diseases and conditions in which angiogenesis is altered. In some embodiments of the invention, a level of a TARS molecule is determined and compared to a control level of TARS to assess onset, progression, and/or regression of a disease or condition associated with altered TARS activity.

The present invention provides an angiogenesis inhibitor containing as an active ingredient LYPD1 protein or a derivative thereof, a part thereof, or a vector expressing the same, or a cell expressing the same. The present invention also provides a screening method for angiogenesis inhibitors that enhance the expression of LYPD1 protein wherein the method includes (i) a step for treating a first cell by a test substance and culturing and (ii) a step for detecting the expression level of LYPD1 protein from the first cell and comparing with the level of LYPD1 protein of an untreated first cell.

Various methods for isolating cell populations from adipocyte tissue and/or blood and quantifying levels of vascular endothelial growth factor receptors (VEGFR) on the isolated cell populations are provided. Also provided are methods of evaluating or modifying angiogenic therapy in a subject.

A peptide that binds specifically to neuropilin-1 (NRP1) without binding to neuropilin-2 (NRP2) is provided. A fusion protein, a fusion antibody, small-molecule drug, a nanoparticle, or a liposome, which comprises the peptide, and a pharmaceutical composition for treating or preventing cancer or angiogenesis-related diseases, and a composition for diagnosing cancer or angiogenesis-related diseases are provided. A polynucleotide encoding the peptide that binds specifically to NRP1 and a method for screening the peptide that binds specifically to NRP1 are provided. An antibody heavy-chain constant region Fc-fused peptide binding specifically to NRP1 has the property of binding specifically to NRP1, and thus when it is administered in vivo, it accumulates selectively in tumor tissue, and widens the intercellular space between tumor-associated endothelial cells to promote its extravasation and increases its tumor tissue penetration.